Benin Management CORP Raises Stock Position in Koninklijke Philips N.V. $PHG

Benin Management CORP grew its holdings in Koninklijke Philips N.V. (NYSE:PHG) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,956 shares of the technology company’s stock after acquiring an additional 2,676 shares during the period. Benin Management CORP’s holdings in Koninklijke Philips were worth $1,582,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Aurora Private Wealth Inc. acquired a new stake in Koninklijke Philips during the 1st quarter valued at $1,695,000. Cerity Partners LLC grew its holdings in Koninklijke Philips by 30.6% during the 1st quarter. Cerity Partners LLC now owns 80,767 shares of the technology company’s stock valued at $2,051,000 after purchasing an additional 18,906 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Koninklijke Philips by 2.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock valued at $111,662,000 after purchasing an additional 106,044 shares in the last quarter. HB Wealth Management LLC acquired a new stake in Koninklijke Philips during the 1st quarter valued at $333,000. Finally, Bessemer Group Inc. grew its holdings in Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after purchasing an additional 1,908 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Price Performance

Shares of PHG stock opened at $28.39 on Wednesday. The firm has a market cap of $27.34 billion, a P/E ratio of 149.42, a P/E/G ratio of 0.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81. Koninklijke Philips N.V. has a 1-year low of $21.48 and a 1-year high of $32.25. The firm has a fifty day moving average of $27.76 and a two-hundred day moving average of $25.43.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.12. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. As a group, research analysts anticipate that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PHG has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Koninklijke Philips in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.